Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Non-Current Debt (2020 - 2024)

Bicycle Therapeutics (BCYC) has disclosed Non-Current Debt for 5 consecutive years, with $8.5 million as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Non-Current Debt fell 72.13% year-over-year to $8.5 million, compared with a TTM value of $8.5 million through Jun 2024, down 72.13%, and an annual FY2023 reading of $30.7 million, up 1.26% over the prior year.
  • Non-Current Debt was $8.5 million for Q2 2024 at Bicycle Therapeutics, down from $30.8 million in the prior quarter.
  • Across five years, Non-Current Debt topped out at $30.8 million in Q1 2024 and bottomed at $8.5 million in Q2 2024.
  • Average Non-Current Debt over 5 years is $26.9 million, with a median of $30.1 million recorded in 2022.
  • The sharpest move saw Non-Current Debt skyrocketed 106.23% in 2021, then plummeted 72.13% in 2024.
  • Year by year, Non-Current Debt stood at $14.5 million in 2020, then soared by 105.95% to $29.9 million in 2021, then increased by 1.48% to $30.3 million in 2022, then rose by 1.26% to $30.7 million in 2023, then plummeted by 72.29% to $8.5 million in 2024.
  • Business Quant data shows Non-Current Debt for BCYC at $8.5 million in Q2 2024, $30.8 million in Q1 2024, and $30.7 million in Q4 2023.